Amneal Pharmaceuticals, Inc. (AMRX)
NASDAQ: AMRX · Real-Time Price · USD
8.38
+0.10 (1.21%)
Mar 31, 2025, 4:00 PM EDT - Market closed
Amneal Pharmaceuticals Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Amneal Pharmaceuticals stock have an average target of 10.8, with a low estimate of 8.00 and a high estimate of 12. The average target predicts an increase of 28.88% from the current stock price of 8.38.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Amneal Pharmaceuticals stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 2 | 2 | 2 | 2 | 2 |
| Buy | 2 | 2 | 2 | 2 | 3 | 3 |
| Hold | 1 | 1 | 1 | 1 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Maintains $10 → $11 | Buy | Maintains | $10 → $11 | +31.26% | Mar 3, 2025 |
| JP Morgan | JP Morgan | Hold → Buy Upgrades $9 → $12 | Hold → Buy | Upgrades | $9 → $12 | +43.20% | Feb 24, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $9 → $11 | Buy | Maintains | $9 → $11 | +31.26% | Nov 11, 2024 |
| Truist Securities | Truist Securities | Strong Buy Maintains $10 → $12 | Strong Buy | Maintains | $10 → $12 | +43.20% | Oct 2, 2024 |
| JP Morgan | JP Morgan | Sell → Hold Upgrades $9 | Sell → Hold | Upgrades | $9 | +7.40% | Sep 6, 2024 |
Financial Forecast
Revenue This Year
3.09B
from 2.79B
Increased by 10.49%
Revenue Next Year
3.30B
from 3.09B
Increased by 7.00%
EPS This Year
0.69
from -0.38
EPS Next Year
0.83
from 0.69
Increased by 19.85%
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 3.2B | 3.5B | 3.8B |
| Avg | 3.1B | 3.3B | 3.7B |
| Low | 2.9B | 3.1B | 3.6B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 14.6% | 12.5% | 15.3% |
| Avg | 10.5% | 7.0% | 12.0% |
| Low | 5.3% | -0.5% | 7.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 0.72 | 0.90 | 1.14 |
| Avg | 0.69 | 0.83 | 0.99 |
| Low | 0.66 | 0.76 | 0.84 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | 30.2% | 37.7% |
| Avg | - | 19.9% | 19.6% |
| Low | - | 10.2% | 1.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.